ArticleTranslational cancer research2026
Tumor mutation burden predicts aggressiveness and prognosis of gastrointestinal stromal tumor.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor mutation burden (TMB) has emerged as a promising predictive biomarker for assessing immunotherapy efficacy and clinical outcomes across a wide range of cancer types. We aim to investigate the prognostic value of TMB in gastrointestinal stromal tumor (GIST) in the present study. Methods: We collected and analyzed data from two independent datasets on the cBioPortal for Cancer Genomics, spanning 1991-2021 and 2015-2021 respectively. All the tumor samples were analyzed by Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) next-generation sequencing. TMB was defined as the total number of somatic non-synonymous mutations per coding area of a tumor genome. The primary outcome was the recurrence-free survival (RFS). Survival analysis was performed by the Kaplan-Meier method and Cox regression analysis were used to perform survival analysis and identify prognostic factors. Results: In total, 317 GIST patients were enrolled. Higher TMB was significantly correlated with larger tumor size (P=0.01), higher mitotic count (P<0.001), risk grade (P<0.001) and presence of metastasis (P=0.003). Non-gastric GIST and older patients exhibited higher TMB compared to gastric GIST and younger patients (P=0.002 and P=0.02, respectively). TMB was significantly correlated with prognosis and was an independent prognostic factor of RFS [hazard ratio (HR) =1.692, 95% confidence interval (CI): 1.106-2.588, P=0.02]. Moreover, high-risk patients with elevated TMB had significantly worse prognosis (P=0.01). Conclusions: TMB appears significantly associated with aggressive clinicopathological features in GIST and serves as an independent prognostic marker. These findings suggest that TMB may hold potential for stratifying GIST patients who may require closer follow-up and more frequent surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.